All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Bookmark this article
During the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub was pleased to speak to Abdul-Hamid Bazarbachi, Jacobi Medical Centre, New York, US. We asked, Is combination anti-thymocyte globulin (ATG) + post-transplantation cyclophosphamide (PTCy) prophylaxis always preferable to using each agent separately in haploidentical hematopoietic cell transplant (haplo-HCT)?
Is combination ATG + PTCy prophylaxis always preferable to using each agent separately in haplo-HCT?
Bazarbachi begins by outlining the indications and efficacy of both high-dose PTCy and ATG as sole therapies in GvHD prophylaxis. He goes on to discuss recent clinical research presented at the 49th Annual Meeting of the EBMT on the use of these treatments concurrently, with a focus on engraftment, relapse, and overall survival. Bazarbachi concludes by describing the implications of this data for the management of patients post haplo-HCT and the resulting incidence of GvHD.
Use of PTCy in GvHD prophylaxis: Findings from a prospective and a retrospective study
Here, we provide an update on the use of PTCy as GvHD prophylaxis from two recent studies; the first by Zu, et al., published in Bone Marrow Transplantation, that...
GvHD prophylaxis using posttransplant cyclophosphamide and antithymocyte globulin after HSCT
Recently, two studies assessed the combined effect of PTCy plus ATG as GvHD prophylaxis in patients with hematological malignancies receiving reduced...
Subscribe to get the best content related to GvHD delivered to your inbox